Solid Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Solid Biosciences LLC
SLDB Stock  USD 5.88  0.04  0.68%   
Solid Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Solid Biosciences' valuation are provided below:
Gross Profit
-96.4 M
Market Capitalization
458.1 M
Enterprise Value Revenue
1.1559
Earnings Share
(2.46)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental trend indicators for Solid Biosciences LLC, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Solid Biosciences LLC current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

Solid Biosciences Total Revenue

8.09 Million

Check Solid Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Solid Biosciences' main balance sheet or income statement drivers, such as Interest Income of 11.4 M, Depreciation And Amortization of 2.1 M or Interest Expense of 371.4 K, as well as many indicators such as Price To Sales Ratio of 10.66, Dividend Yield of 0.0 or PTB Ratio of 1.12. Solid financial statements analysis is a perfect complement when working with Solid Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Solid Stock
Check out the analysis of Solid Biosciences Correlation against competitors.

Solid Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets157.6 M217 M122.7 M
Slightly volatile
Other Current Liabilities27.8 M26.5 M13.5 M
Slightly volatile
Total Current Liabilities19.6 M34.8 M17.8 M
Slightly volatile
Accounts Payable4 M4.9 M2.9 M
Slightly volatile
Cash91.8 M92.3 M68.3 M
Slightly volatile
Cash And Short Term Investments133.9 M171.3 M105.8 M
Slightly volatile
Common Stock Total Equity17.1 K18 K4 M
Very volatile
Common Stock Shares Outstanding49.3 M46.9 M11.3 M
Slightly volatile
Liabilities And Stockholders Equity157.6 M217 M122.7 M
Slightly volatile
Non Current Liabilities Total28.1 M19 M41.6 M
Slightly volatile
Other Current Assets5.8 M9.6 M4.1 M
Slightly volatile
Total Liabilities42.3 M46.3 M58.6 M
Slightly volatile
Preferred Stock Total Equity94.4 M142.8 M98.4 M
Slightly volatile
Total Current Assets139.6 M180.9 M109.9 M
Slightly volatile
Common Stock34.2 K36 K3.9 M
Very volatile
Property Plant And Equipment Net18.3 M33.4 M12 M
Slightly volatile
Current Deferred Revenue6.7 M9.3 M4.6 M
Slightly volatile
Non Current Assets Total20 M36.1 M13.2 M
Slightly volatile
Non Currrent Assets Other1.6 M2.7 M1.1 M
Slightly volatile
Other Assets1.091.15702.4 K
Very volatile
Deferred Long Term Liabilities3.8 M3.6 M1.9 M
Slightly volatile
Property Plant And Equipment Gross24.3 M48.4 M16.1 M
Slightly volatile
Property Plant Equipment9.1 M11.1 M5.9 M
Slightly volatile
Net Working Capital139.8 M146.1 M101.1 M
Slightly volatile
Short and Long Term Debt Total14.8 M27.8 M8.5 M
Slightly volatile
Other Liabilities82.1 K86.4 K2 M
Very volatile
Long Term Debt Total636.8 K659.7 K789.7 K
Slightly volatile
Capital Surpluse597.6 M890.6 M491 M
Slightly volatile
Capital Lease Obligations14.8 M27.8 M8.5 M
Slightly volatile
Capital Stock41.4 K36 K42.3 K
Pretty Stable
Short Term Debt2.2 M3.5 M1.3 M
Slightly volatile
Inventory4.8 M5.4 M5.9 M
Slightly volatile

Solid Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income11.4 M10.9 M2.6 M
Slightly volatile
Depreciation And Amortization2.1 M2.2 M3.7 M
Slightly volatile
Selling General Administrative22.4 M38.3 M16.3 M
Slightly volatile
Other Operating Expenses88.3 M149.2 M63.1 M
Slightly volatile
Research Development65.1 M110.9 M46.4 M
Slightly volatile
Total Operating Expenses87.3 M146.4 M62.4 M
Slightly volatile
Net Interest Income11 M10.5 M2.7 M
Slightly volatile
Reconciled Depreciation2.7 M2.8 M1.7 M
Slightly volatile
Non Operating Income Net Other24.7 M23.5 M7.7 M
Slightly volatile
Non Recurring5 M8.3 M3.7 M
Slightly volatile
Selling And Marketing Expenses2.1 M2.3 M2.5 M
Slightly volatile

Solid Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation8.6 M12.1 M6.1 M
Slightly volatile
Begin Period Cash Flow84.4 M87.2 M57.6 M
Slightly volatile
Depreciation2.1 M2.8 M1.4 M
Slightly volatile
Capital Expenditures559.2 K588.6 K1.5 M
Pretty Stable
Total Cash From Financing Activities86.4 M140.8 M74.7 M
Slightly volatile
End Period Cash Flow92.5 M94.5 M68.9 M
Slightly volatile
Issuance Of Capital Stock82.9 M114.5 M117.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.666.5111.6922
Slightly volatile
Days Sales Outstanding2.362.652.8958
Slightly volatile
Stock Based Compensation To Revenue1.061.070.9827
Pretty Stable
Capex To Depreciation0.290.312.9723
Slightly volatile
Payables Turnover0.520.57940.4708
Slightly volatile
Sales General And Administrative To Revenue2.223.222.3575
Slightly volatile
Research And Ddevelopement To Revenue5.68.725.5964
Slightly volatile
Capex To Revenue0.180.340.1627
Slightly volatile
Cash Per Share3.994.230.83
Slightly volatile
Days Payables Outstanding6887248.4 K
Slightly volatile
Income Quality0.70.720.7785
Slightly volatile
Current Ratio5.954.686.615
Pretty Stable
Receivables Turnover99.06111122
Slightly volatile
Debt To Equity0.170.160.0624
Slightly volatile
Capex Per Share0.01750.01840.5447
Very volatile
Revenue Per Share1.571.091.6749
Slightly volatile
Interest Debt Per Share0.660.690.8954
Slightly volatile
Debt To Assets0.05850.120.0441
Slightly volatile
Operating Cycle2.362.652.8958
Slightly volatile
Days Of Payables Outstanding6887248.4 K
Slightly volatile
Ebt Per Ebit1.061.110.9906
Very volatile
Long Term Debt To Capitalization0.00550.00610.0067
Slightly volatile
Total Debt To Capitalization0.140.130.0537
Slightly volatile
Debt Equity Ratio0.170.160.0624
Slightly volatile
Quick Ratio5.954.686.615
Pretty Stable
Net Income Per E B T0.760.880.9487
Slightly volatile
Cash Ratio3.592.393.5967
Slightly volatile
Days Of Sales Outstanding2.362.652.8958
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.161.0431
Slightly volatile
Fixed Asset Turnover0.230.241.329
Slightly volatile
Debt Ratio0.05850.120.0441
Slightly volatile
Price Sales Ratio10.666.5111.6922
Slightly volatile
Asset Turnover0.04940.03580.0519
Slightly volatile

Solid Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap36.6 M41.2 M45 M
Slightly volatile

Solid Fundamental Market Drivers

Solid Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Solid Biosciences Financial Statements

Solid Biosciences stakeholders use historical fundamental indicators, such as Solid Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Solid Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Solid Biosciences' assets and liabilities are reflected in the revenues and expenses on Solid Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Solid Biosciences LLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue9.3 M6.7 M
Cost Of Revenue2.8 M2.1 M
Stock Based Compensation To Revenue 1.07  1.06 
Sales General And Administrative To Revenue 3.22  2.22 
Research And Ddevelopement To Revenue 8.72  5.60 
Capex To Revenue 0.34  0.18 
Revenue Per Share 1.09  1.57 
Ebit Per Revenue(15.12)(15.88)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:
How To Invest In Solid
Details
Is Solid Stock a good investment?
Details
What is Solid Biosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Solid Biosciences Correlation against competitors.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Solid Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(2.46)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.44)
Return On Equity
(0.87)
Understanding Solid Biosciences LLC requires distinguishing between market price and book value, where the latter reflects Solid's accounting equity. The concept of intrinsic value - what Solid Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Solid Biosciences' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Solid Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY